慢性移植物抗宿主病持续七年以上的临床特征与细胞因子标志物
研究纳入38例持续≥7年的慢性GVHD患者和83例早期(<1年)患者,比较临床与生物学特征。多变量分析显示骨髓干细胞来源、ENA自身抗体、较高NIH肺部评分、较高血小板和IgA水平与持续cGVHD相关,持续组BAFF和CXCL10水平显著降低。结论认为常规疾病严重程度指标可能不能准确反映持续cGVHD的活动性,许多患者仍在接受全身免疫抑制治疗但缺乏疾病活动证据。
要点
- 骨髓干细胞来源、ENA自身抗体、较高NIH肺部评分、较高血小板和IgA水平与持续cGVHD显著相关。
- 持续cGVHD患者血清BAFF和CXCL10水平显著低于早期cGVHD患者。
核心结论
- 常规疾病严重程度指标可能不能准确反映持续cGVHD患者的疾病活动性。
- 许多持续cGVHD患者仍在接受全身免疫抑制治疗但缺乏疾病活动证据。
- 开发可靠的cGVHD活动性临床生物标志物可能有助于指导未来的全身治疗。
研究设计与样本
- 前瞻性横断面自然病史研究,纳入持续cGVHD患者38例和早期cGVHD患者83例。
- 持续cGVHD组距cGVHD诊断中位时间10.2年(范围7-27年)。
主要发现
- 多变量分析显示骨髓干细胞来源、ENA自身抗体存在、较高NIH肺部评分、较高血小板计数和较高IgA水平与持续cGVHD显著相关。
- 持续cGVHD患者血清BAFF和CXCL10水平显著低于早期cGVHD患者。
临床怎么用
- 对持续cGVHD患者应评估疾病活动性而非仅依据常规严重程度指标决定是否继续免疫抑制治疗。
- BAFF和CXCL10等细胞因子可能作为辅助生物标志物帮助判断持续cGVHD的活动状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic graft-versus-host disease (cGVHD) is the leading late complication after allogeneic hematopoietic stem cell transplantation (HSCT). Many patients receive multiple lines of systemic therapy until cGVHD resolves, but about 15% remain on systemic treatment for more than 7 years after cGVHD diagnosis. This study describes the clinical and biological factors of patients who present with cGVHD persisting for ≥7 years (persistent cGVHD). Patients with persistent cGVHD (n = 38) and those with cGVHD for <1 year (early cGVHD) (n = 83) were enrolled in a prospective cross-sectional natural history study. Patients in the persistent cGVHD group were a median of 10.2 years from cGVHD diagnosis (range 7-27 years). Fifty-eight percent of persistent cGVHD patients (22/38) were receiving systemic immunosuppression, compared to 88% (73/83) in the early cGVHD group. In multivariable analysis, bone marrow (BM) stem cell source, presence of ENA autoantibodies, higher NIH lung score, higher platelet counts, and higher IgA levels were significantly associated with persistent cGVHD. A high sensitivity panel of serum biomarkers including seven cytokines diagnostic for cGVHD was analyzed and showed significantly lower levels of BAFF and CXCL10 in patients with persistent cGVHD. In conclusion, standardly accepted clinical measures of disease severity may not accurately reflect disease activity in patients with persistent cGVHD. However, many patients with persistent cGVHD are still receiving systemic immunosuppression despite lacking evidence of disease activity. Development of reliable clinical biomarkers of cGVHD activity may help guide future systemic treatments.
引用
- Goklemez S, Im AP, Cao L, et al. Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis. Am J Hematol. 2020. PMID: 31903638. doi:10.1002/ajh.25717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。